JAK Inhibitor Effectiveness in Giant-Cell Arteritis With Large-Vessel Involvement Assessed by 18F-FDG PET-CT

Clin Nucl Med. 2022 Mar 1;47(3):234-235. doi: 10.1097/RLU.0000000000003913.

Abstract

We report the case of a 76-year-old woman with relapsing giant-cell arteritis and large-vessel vasculitis demonstrated on 18F-FDG-PET/CT. Methotrexate and tocilizumab failed to achieve remission, and the patient ultimately exhibited a favorable clinical and radiological response to baricitinib, a JAK inhibitor. This case suggests that baricitinib may be a promising treatment for giant-cell arteritis-related large-vessel vasculitis and that 18F-FDG-PET/CT may be used to monitor therapeutic response.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Arteritis*
  • Female
  • Fluorodeoxyglucose F18
  • Giant Cell Arteritis* / diagnostic imaging
  • Giant Cell Arteritis* / drug therapy
  • Humans
  • Janus Kinase Inhibitors*
  • Positron Emission Tomography Computed Tomography
  • Radiopharmaceuticals
  • Takayasu Arteritis*

Substances

  • Janus Kinase Inhibitors
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18